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ABSTRACT
Introduction: The Valsalva manoeuvre (VM) is a
recommended first-line physical treatment for patients
with re-entrant supraventricular tachycardia (SVT), but
is often ineffective in standard practice. A failed VM is
typically followed by treatment with intravenous
adenosine, which patients often find unpleasant. VM
effectiveness might be improved by a modification to
posture which exaggerates the manoeuvre’s vagal
response and reduces the need for further emergency
treatment.
Methods and analysis: This is a multicentre
randomised controlled clinical trial in 10 UK emergency
departments (EDs). It compares a standard VM with a
modified VM incorporating leg elevation and a supine
posture after a standardised strain in stable adult
patients presenting to the ED with SVT. The primary
outcome measure is return to sinus rhythm on a
12-lead ECG. Secondary outcome measures include
the need for treatment with adenosine or other
antiarrhythmic treatments and the time patients spend
in the ED. We plan to recruit approximately 372
patients, with 80% power to demonstrate an absolute
improvement in cardioversion rate of 12%. An
improvement of this magnitude through the use of a
modified VM would be of significant benefit to patients
and healthcare providers, and justify a change to
standard practice.
Ethics and dissemination: The study has been
approved by the South West—Exeter Research Ethics
Committee (REC reference 12/SW/0281). The trial will
be published in an international peer reviewed journal.
Study findings will be sent to the European and
International resuscitation councils to inform future
revisions of arrhythmia management guidelines.
Results: The trial will also be disseminated at
international conferences and to patients through the
Arrhythmia Alliance, a patient support charity.
Registration: The study is registered with Current
Controlled Trials (ISRCTN67937027) and has been
adopted by the National Institute for Health Research
(NIHR) Clinical Research Network.
INTRODUCTION
Supraventricular tachycardia (SVT) is a
common heart rhythm disorder with an
estimated incidence of 35 episodes per
100 000 persons/year.1 It usually occurs due
to the presence of an accessory electrical
pathway within the heart, causing re-entrant
tachycardia. Episodes can be self-limiting but
often recur and attacks are very unpleasant
and disruptive to patients’ lives.2 3 Patients
often come to the emergency department
(ED) during attacks: annually about 50 000
attend an ED in the USA.4 In the UK, about
125 000 people are affected and 50–100
patients will attend an average UK ED with
SVT each year (unpublished UK regional
audit data).
International first-line emergency treat-
ment guidelines for stable SVT advocate
attempted cardioversion with a vagal man-
oeuvre.5 6 The Valsalva manoeuvre (VM) is
very safe, and the most effective vagal man-
oeuvre in adults.7 However, it is performed
Strengths and limitations of this study
▪ This is the first randomised controlled trial inves-
tigating the effects of a postural modification to
the Valsalva manoeuvre (VM) to treat patients
presenting with supraventricular tachycardia in
an emergency department setting.
▪ This pragmatic study is designed to detect a
meaningful improvement in the efficacy of the
VM using a novel and easily achieved modifica-
tion to the manoeuvre for the benefit of patients.
▪ Although blinding of participants and clinicians
is not practically possible, participants will not
be told which is the ‘new’ technique and blinded
analysis of results and independent review of the
primary outcome will be undertaken.
▪ The study is designed to detect a 12% absolute
improvement in cardioversion rate with the modi-
fied VM. This effect size was chosen based on
the best available evidence and on a magnitude
that we felt would be needed to convince clini-
cians to change practice, but as a result, the
study risks being underpowered to detect a
smaller difference in efficacy.
Appelboam A, Reuben A, Mann C, et al. BMJ Open 2014;4:e004525. doi:10.1136/bmjopen-2013-004525 1
Open Access Protocol
group.bmj.com on January 9, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
inconsistently8 and has a relatively low (5–20%) cardio-
version success rate in clinical practice.9 10 Patients who
remain in SVT after a VM are usually treated with intra-
venous adenosine. While effective, this drug causes
unpleasant side effects. Some patients report that they
feel as though they are about to die; many find this treat-
ment frightening or unpleasant, and significant adverse
events have been reported.2 11 Other emergency treat-
ments for SVT such as direct current cardioversion are
invasive and also not without risk.
Performing the most effective VM will reduce the
number of patients presenting in SVT who need to
undergo further emergency treatment, and may also
increase the number of patients who are able to manage
their own condition in the community, without the need
to attend hospital.
The efficacy of the VM might be influenced by the
duration and intensity of the strain or the position of
the patient. Current evidence would suggest that the
optimal strain duration is 15 s with a minimum pressure
of 40 mm Hg,9 although this strain is not routinely stan-
dardised.12 The effect of patient position during emer-
gency VM has not been well studied, but posture
modifications to increase venous return and vagal stimu-
lation in the relaxation phase may improve VM effi-
cacy.13–16 There have been no randomised clinical trials
assessing the effect of patient position during the VM in
ED patients presenting with SVT. Although greater vagal
tone is achieved in normal participants with a supine
VM,17 it is not known whether this results in a higher
cardioversion rate in patients with SVT,13 and the stand-
ard VM is typically performed in the semirecumbent
position in the ED.8 14 18
In a non-randomised before and after study, the intro-
duction of a head down (Trendelenburg) position VM
into routine practice was associated with an improve-
ment in cardioversion from 5% to 31%.14 This was a
very small (19 patient), uncontrolled observational study
and its results might not be generalisable to the larger
ED population. However, it has been suggested that a
further surge in venous return (and thus vagal stimula-
tion) can also be achieved during the relaxation phase,
immediately after the Valsalva strain, by laying the
patient flat from sitting and lifting the patient’s legs (the
modified VM).13 15 Anecdotally, this modification has
often been successful when a standard VM has failed.16
Although the modified VM is based on sound physio-
logical principles and is used by some emergency physi-
cians in our region,18 the effect of this modification on
cardioversion rates in ED patients has not been previ-
ously studied and is not in widespread global use.
Our study has been designed to determine whether
such a modification to the standard VM is more effective
in converting SVT to sinus rhythm than the standard
sitting VM in stable adult patients presenting to the ED
with SVT. A clinically significant improvement in the
success rate of the VM using a simple, safe modification
to patient positioning during the manoeuvre would be
an important discovery, with major benefits for patients
and for emergency healthcare providers around the
world, and is likely to influence international tachyar-
rhythmia guidelines.
METHODS AND ANALYSIS
General study design and conduct
This study is a randomised, assessor blind, multicentre
parallel group trial in stable adult patients presenting to
the UK EDs with SVT. Three hundred and seventy-two
participants will be randomised in a 1:1 ratio to undergo
a standardised Valsalva (15 s, 40 mm Hg) strain as either
a ‘standard’ (control) VM, performed in a semirecum-
bent position (sitting at 45°), or as a ‘modified’ (inter-
vention) VM, performed semirecumbent but followed
immediately by being laid flat with the patient’s legs pas-
sively raised to 45° for a further 15 s after the strain. This
is an open study, but participants’ study allocations will
be blinded to those performing a central review of ECGs
and the statistician analysing the results.
The key objective of the study was to determine
whether a modified VM is better at restoring sinus
rhythm (as determined by a 12-lead ECG read by the
treating clinician) at 1 min post-manoeuvre in adult
patients with SVT compared with the standard VM.
We will also assess the impact of a modified VM on the
subsequent need for adenosine and other emergency
treatments, on the time patients spend in the ED and
on the need for admission to hospital. We will also
monitor any side effects or complications of using a
modified VM compared to the standard VM. All ECGs
will be centrally reviewed by an independent cardiologist
to confirm the treating clinician’s interpretation.
Patient and public involvement was ensured at all
stages of trial design and conduct through patient and
patient support group representation on the trial man-
agement group, trial steering committee (TSC) and
authorship. Day-to-day trial management is administered
through the UKCRC-registered Peninsula Clinical Trials
Unit (CTU) at Plymouth University and sponsored by
the Royal Devon and Exeter National Health Service
(NHS) Foundation Trust.
Study procedures
Study population and setting
All adult patients (aged 18 and over), presenting to par-
ticipating EDs (see Participating hospitals) at any time
with suspected SVT, will be considered for inclusion in
the trial. Unstable patients with systolic blood pressure
less than 90 mm Hg or any indication for immediate car-
dioversion, those unable to consent or perform the trial
VMs and those in whom the trial interventions could
conceivably cause harm will be excluded. Full inclusion
and exclusion criteria for the trial are summarised in
box 1.
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Screening, recruitment and consent
The screening and recruitment of patients, delivery of
the intervention and recording of outcomes will all be
carried out within participating UK NHS EDs. It is usual
UK practice that patients who come to the ED with pal-
pitations or tachycardia have an ECG performed on
arrival, which is reviewed by a senior ED clinician.
Patients presenting to the ED with SVT confirmed by an
ECG review will be screened for eligibility by Good
Clinical Practice (GCP) trained staff. Eligible patients
will, by definition, be stable and not in imminent
danger; therefore, there will be reasonable time in the
ED to obtain informed consent from each participant.
Additional checks and reminders will be employed to
ensure that all eligible patients have equal opportunity
to participate. ED attendance logs will be screened for
the duration of the trial to enable the identification of
any missed patients with reporting of simple demo-
graphic data to ensure that there is no evidence of
recruitment bias.
The written informed consent process will normally
be undertaken by the attending clinician, but may be
delegated to another appropriate member of the
research team depending on individual circumstances.
Study team members nominated by the principal investi-
gator to undertake the consent process will be listed as
such on the study delegation log.
Eligible patients will be provided with an initial
summary participant information sheet, a verbal explan-
ation of the purpose and nature of the trial and a
description of what participation in the trial will entail.
Patients will be given the opportunity to ask questions
about the study. Following this verbal and written
explanation, patients who are interested and eligible will
be invited to participate in the study. If a patient agrees
to participate, he/she will be asked to complete an
Informed Consent Form which will be countersigned by
the staff member taking consent. This will include a
signed statement that the patient cannot foresee any
reason that the standard or modified VM should cause
them any difficulty or discomfort. A record of the
patient’s consent to participate will be documented in
the hospital notes where a copy of the completed
consent form and participant information sheet will also
be filed.
Baseline assessment and ECG
Study participants will undergo standard clinical assess-
ment in the ED, including medical history, physical
examination, recording of routine initial observations of
pulse, blood pressure, respiratory rate, oxygen saturation
and the recording of a (pre-VM) 12-lead ECG. Baseline
data required for the purposes of the trial will be
recorded on a study specific case report form (CRF) by
the research nurse or nominated research team
member. This includes time of arrival in the ED, demo-
graphic data, medical history (including previous SVT),
current medication, prehospital care (including any VM
attempts) and baseline vital signs. All concurrent medi-
cations will be recorded on the CRF. There are no con-
current medications which would preclude trial
participation.
Randomisation:
After consent has been obtained, participants will be
randomised to receive the standard VM (control) or the
modified VM (intervention) as the first treatment for
their SVT. Treatment allocations will be randomly deter-
mined using variable-sized blocking and stratified by
centre. The randomisation sequence will be prepared by
an independent statistician using proprietary software,
and then passed to the CTU for preparation of alloca-
tion cards. These cards will be placed in sequentially
numbered opaque sealed envelopes, independently and
in advance, by the CTU and provided to participating
sites.
These envelopes will be tested for 100% concealment
and closed with a tamper-proof seal, preventing opening
and resealing. Envelopes will be securely stored in a
locked ED cupboard at each site, access to which is con-
trolled by a senior nurse, who is independent to the
study but always present when potentially eligible
patients attend the ED. Envelopes will be sequentially
released by the CTU in small batches sufficient to
support projected recruitment and replace used envel-
opes. Envelopes will only be accessed after participant
consent and with the agreement of the recruiting doctor
and resuscitation room nurse.
The treatment will be allocated by selecting the next
presealed randomisation envelope in sequence. The
number on the envelope will be checked against a ran-
domisation log to ensure that the correct envelope has
Box 1 REVERT study inclusion and exclusion criteria
Inclusion criteria
1. Age 18 years and older
2. Diagnosis of supraventricular tachycardia (SVT; regular,
narrow complex tachycardia with QRS duration <0.12 s on
ECG)
Exclusion criteria
1. Unable or unwilling to give informed consent
2. Unstable condition (systolic blood pressure (BP) <90 mm Hg
or any indication for immediate drug or direct current
cardioversion)
3. Atrial fibrillation or atrial flutter on ECG
4. Suspected atrial flutter requiring a trial of adenosine
5. Severe hypertension (systolic BP>220 mm Hg or diastolic
BP>120 mm Hg)
6. Any contraindication to or inability to performing a Valsalva
manoeuvre
7. Contraindication or inability to lay flat and have legs lifted (or
any reason identified by the patient as to why this manoeuvre
would cause discomfort or pain)
8. Third trimester pregnancy
9. Previous inclusion in the study
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been selected. The recruiting doctor or nurse will com-
plete the randomisation log each time an envelope is
taken for use and will sign and date the envelope across
the unbroken seal to confirm that the next available and
lowest numbered envelope of the batch has been taken,
that it is unopened and bears no evidence of tampering.
The participant’s initials and date of birth will also be
written on the envelope prior to opening. Correct and
sequential use of envelopes will be strictly audited by the
site research team and CTU trial manager.
Trial interventions
Consenting, eligible patients will be randomised to the
standard (control) or modified (intervention) VM,
using standardised manoeuvres according to instructions
and training provided specifically for the trial.
Participants in both groups will be placed in a semire-
cumbent position, sitting at an angle of 45°, for at least
1 min prior to undertaking the VM. All patients will
have standard monitoring including a continuous 3-lead
ECG, non-invasive blood pressure monitoring and
oxygen saturation monitoring during any VM.
Standard VM (control)
Participants will be seated at a 45° angle, and will
perform the standardised strain for 15 s and remain in
this seated position for 60 s. To reduce bias, this alloca-
tion will be described to patients as the ‘stay sitting
Valsalva’.
Modified VM (intervention)
Participants will be seated at a 45° angle, and will
perform the standardised strain for 15 s. Following this,
they will be laid flat, and their legs will be raised by ED
staff to a 45° angle for 15 s. Participants will then be
returned to the 45° semirecumbent position for 45 s. To
reduce bias, this allocation will be described to patients
as the ‘lying down with leg lift Valsalva’.
Standardised strain
Participants in both groups will be instructed to perform
a standardised strain (VM) for which instructions are
provided specifically for the trial and printed on the
reverse of each allocation card. This consists of a forced
expiration against a manometer (Welch Allyn) to a pres-
sure of 40 mm Hg for 15 s, through a disposable 3 mm
green (bubble) oxygen tubing (Uhs Ref:UN881) cut at
its widest point for the mouth end and at 92 cm to allow
connection to the meter. The meter, marked with the
target pressure and a timer, will be visible to the partici-
pant, the treating clinician and attending nurse. During
the strain, clinicians will give standardised verbal encour-
agement at 5 and 10 s to support participants in achiev-
ing target pressure and strain duration. A stopwatch is
attached to the manometer for consistent timings. If
sinus rhythm is not restored, according to a 3-lead ECG
monitoring, patients in both groups will be invited to
undertake one further VM of the allocated type.
The clinician will record on the reverse of the alloca-
tion card whether the allocated VM was attempted and
the peak pressure and the total duration of strain
achieved. The duration of the longest strain will be
recorded if more than one attempt was needed during
the 15 s period. This information will be used to report
whether the Valsalva was performed correctly, though
since statistical analyses will be on an intention to treat
basis, participants performing the manoeuvre incorrectly
will not be excluded from the study. The attending clin-
ician or nurse will also ask the participant if the VM
caused any discomfort or problems and will record the
response together with any technical problems or clin-
ical adverse effects that occurred during the VM.
Postintervention management
Patients will be left in position for 1 min after the VM
before undergoing a repeat (post-VM) 12-lead ECG.
This will ensure that very transient non-sustained return
to sinus rhythm during the manoeuvre, which can
occur, is not recorded as a treatment success. Individual
trial participation will last from the time of patient
consent until the recording of this postintervention
(Valsalva) ECG (figure 1). Typically, this process will
take less than 1 h.
Subsequent management of the patient will be
entirely according to standard clinical guidelines with
no further trial intervention. Participants will be fol-
lowed up until ED discharge or hospital admission with
details of any further ED treatments for SVT recorded.
The time of ED discharge will be verified from the
patient tracking system and recorded in the CRF. For the
purposes of the study, ED discharge is defined as dis-
charge to an inpatient or observation ward or discharge
out of the hospital. Time spent in an ED observation
ward, for example, awaiting transport home, will not be
included in the total time spent in the ED.
Prior to discharge, all participants will be given a
more detailed information sheet about the study, includ-
ing written instructions on how to perform both types of
VM themselves once they have left hospital. An equiva-
lent Valsalva strain can be achieved by blowing into a
10 mL syringe with just enough force to move the
plunger and an unused syringe will also be given to all
trial patients to take away.19 The information sheet will
include a weblink to the Arrhythmia Alliance website
(http://www.arrhythmiaalliance.org.uk), where informa-
tion will be posted at the end of the trial explaining
which manoeuvre has been shown to be most effective.
Independent ECG review
Copies of pre-VM and post-VM ECGs will be made and
labelled with the participant’s initials and trial number
to preserve anonymity. All ECGs will be reviewed by an
independent assessor (consultant cardiologist) blind to
treatment allocation and not a member of the research
team. Any disagreement when compared with the clinic-
ally recorded assessment, or any other uncertainty in
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ECG diagnosis, will be arbitrated by a consultant cardi-
ology electrophysiologist blind to group allocation.
Safety monitoring
The VM is a safe, standard recommended intervention
and the trial has no separate data safety monitoring
committee. However, the trial exclusion criteria were
designed to exclude patients in whom either trial VM
could conceivably cause harm and staff have been
trained to document and report all adverse events occur-
ing at any point during trial participation. All suspected
serious adverse events (SAEs) will be reported, within
24 h of discovery, to the CTU who will notify the chief
investigator, the TSC and the trial sponsor. All SAEs will
be followed up until resolution.
A summary report of all serious and non-SAEs will be
scrutinised by members of the TSC on a quarterly basis.
The TSC and trial sponsor have the authority to stop the
trial if any indication of harm is found. The trial will be
fully compliant with GCP guideline standards for
adverse event reporting.
Hypothesis and effect size
The null hypothesis for the trial is that there is no differ-
ence in cardioversion rates of SVT between the standard
and modified VM. Given the availability of an effective,
Figure 1 REVERT study flow diagram.
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albeit unpleasant, drug treatment for SVT, we felt that a
clinically significant difference between the two groups
would need to be at least in the magnitude of 10–15 per-
centage points to persuade clinicians to change their
practice. This effect size, while large, is substantially less
than that reported in the best currently available evi-
dence (absolute improvement of 26% seen in a non-
randomised trial).14
Primary outcome measure
The primary outcome for the study will be the presence
of sinus rhythm as determined by the 12-lead ECG per-
formed 1 min after the Valsalva attempt, read by the
treating clinician.
Secondary outcome measures
Secondary outcomes will include: the use of adenosine
(including doses and number of treatments), the use of
other ED treatments for SVT, the need and reason for
admission to hospital, as documented in the hospital
notes, and the length of time participants spent in the
ED, as recorded by the hospital electronic patient track-
ing systems. The number and nature of any adverse
events and the confirmation of the cardiac rhythm on
the post-Valsalva ECG, as determined by a consultant
cardiologist (arbitrated by an electrophysiologist in the
event of disagreement with the treating clinician’s inter-
pretation), will also be reported.
Determination of sample size
Local audit data and previous ED studies suggest a
standard VM baseline success rate of about 15%. To
demonstrate a 12% absolute improvement from this
baseline to a 27% cardioversion rate with a modified VM
will require an estimated 186 patients per group. This
calculation assumes a two-tailed test of statistical signifi-
cance with an α level of 0.05 and power of 0.8.
To achieve this sample size, we estimated that a
22-month recruitment period across at least nine centres
would be needed. This is based on a conservative mean
attendance rate of 1.8 adult SVT patients per week seen
in local audit and a recruitment rate of around 25% of
eligible adult patients attending with SVT, after exclud-
ing 10% of patients who had one or more trial exclusion
criteria (unpublished audit data). As the trial participa-
tion period is so short, study dropout would be expected
to be restricted to participants withdrawing consent
prior to or during the intervention, or participants with
spontaneous cardioversion between recruitment and
trial intervention. We expect rates of these to be very
low, and so we have not included any extra participants
in the sample size calculations to compensate for this,
but dropout rates will be carefully monitored and
recruitment increased through the addition of further
recruiting centres if needed to ensure that the planned
sample size is achieved.
Data analysis
A detailed statistical analysis plan, detailing the exact
analyses to be conducted and reported, will be devel-
oped prior to any comparative analysis. All analyses will
be conducted using a database containing codes for
group allocation without indicating which specific group
each code refers to. A CONSORT20 diagram will be used
to report numbers of patients screened, recruited and
randomised. It will also detail numbers receiving each
procedure and any dropouts.
There is no opportunity for cross-over of trial treat-
ments except in the case of error. If such an error
occurs, participants will be analysed according to their
trial allocation on an intention-to-treat basis.
Baseline data (eg, demographics and medication) will
be reported descriptively by group. All comparative ana-
lyses will be conducted in accordance with intention-
to-treat principles and reported with suitable point
estimates, 95% CIs and p values. Sensitivity analyses will
be conducted for any missing data or protocol violations.
Rates of successful cardioversion to sinus rhythm will be
compared using a logistic regression with allocation
group and centre as fixed effects. Similar analyses will be
conducted for receipt of further treatments and hospital
admission. Time spent in the ED will be compared
using time-to-event methods, namely a Cox Proportional
Hazards model (including centre).
We considered collecting prehospital data on duration
of symptoms of SVT and prior (eg, patient or para-
medic) VM attempts. These data, however, are not rou-
tinely, accurately or reliably recorded and do not usually
influence ED management or preclude use of a VM as
first-line ED treatment. Therefore, to maintain the trial’s
simplicity and pragmatic approach, we did not design
the study to collect such prehospital information.
Although prior VM attempts or duration of SVT could
potentially act as confounders, we felt that randomisa-
tion and allocation concealment would sufficiently
control this potential allocation and recruitment bias.
We also considered, but decided against, an analysis of
the relative frequency of SVT subtypes, for example,
atrioventricular nodal re-entry tachycardia and atrioven-
tricular nodal re-entry tachycardia (AVNRT) in partici-
pants. This is not a subdiagnosis routinely made by
treating emergency physicians; nor is it one which influ-
ences SVT treatment in the ED. Furthermore, the data
being collected (pre-Valsalva and post-Valsalva ECGs)
would not alone allow reliable retrospective subtyping of
the ECGs. No interim analyses are planned.
Missing data
Given the nature of the short follow-up and limited
amount of data to be collected, it is not anticipated
that there will be a significant quantity of missing data.
Every attempt will be made to retrieve any missing
data. Where there remain missing data, sensitivity ana-
lyses may be conducted using a range of assumptions
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where necessary, and consideration given to suitable
imputation.
Data monitoring
Although there is no formal data monitoring committee,
rates of overall cardioversion and adverse event data will
be monitored by the TSC to ensure safety. Rates of post-
randomisation (pre-Valsalva) spontaneous cardioversion
will be monitored, as spontaneous cardioversion does
occur in SVT. Numbers of patients recruited whose final
or expert presenting ECG diagnosis was other than SVT
(eg, some cases of atrial flutter can be misinterpreted as
a re-entrant SVT) will also be monitored. Although
these cases will still be analysed on an intention-to-treat
basis under their original treatment allocations, add-
itional patients will be recruited to ensure that there are
sufficient numbers of genuine SVT cases undergoing
trial intervention to meet the prespecified sample size
calculations.
Ethics and dissemination
The trial complies with the Declaration of Helsinki and
GCP guidelines. All eligible, willing participants will
undergo written informed consent by GCP trained staff
before taking part in the study.
The results of the study will be applicable and of inter-
est to emergency physicians, paramedics, acute physi-
cians, general practitioners and patients. We aim to
disseminate the findings of the study to these groups
through publication of the trial in an appropriate inter-
national peer reviewed journal and through presenta-
tions at local, national and international academic
meetings such as the College of Emergency Medicine
scientific meeting and International Conference of
Emergency Medicine. Chairs of the UK, European and
International resuscitation councils will also be informed
of the results in order to inform subsequent guidelines
for the acute management of SVT.
All patients recruited into the study will be offered an
instruction sheet detailing how to perform both VMs
themselves, and where to find out the results of the trial
through the Arrhythmia Alliance and its website. The
results will also be accessible to people with SVT outside
the study through this patient support organisation. At
the conclusion of the study, this website will also provide
guides for patients and professionals on how to perform
the most effective VM, both in and out of hospital. Links
to this resource will be sent to administrators of estab-
lished online medical education sites which include the
management of cardiovascular emergencies.
DISCUSSION
The Randomised Evaluation of modified Valsalva
Effectiveness in Re-entrant Tachycardias (REVERT) trial
is the first randomised controlled trial to assess the
effect of modification to the VM in the treatment of
patients presenting to the ED with SVT. It aims to
discover whether a simple postural modification to the
standard VM is more effective in returning patients to
sinus rhythm, and reducing the number of patients who
need to proceed to unpleasant drug treatment. This
would have potential benefits for patients around the
world who suffer from SVT both in and out of hospital
as this treatment can be performed by the patient them-
selves without specialist drugs or equipment.
The trial has been designed with patients in mind,
involved patients throughout the process and addresses
a frequently occurring problem. It is a pragmatic study
carried out in the environment where these patients are
normally treated, and where the results will be applied.
The study is based on routine current treatment, with
appropriate modifications to ensure robust trial method-
ology, and complies with guidelines for randomised
trials.20 The trial has also been specifically designed to
meet its objectives and recruitment targets in the chal-
lenging ED environment using a carefully considered
effect size and accrual rate, based on data from partici-
pating sites and previous research. We believe the trial
will therefore be able to deliver these objectives within
the allocated time and resources. The proposed modifi-
cations to the VM do not interfere with or replace spe-
cialist treatment or referral plans, or impact on
long-term treatment options such as accessory pathway
radiofrequency ablation.
Benefits of demonstrating an improved VM would
include the reduced need for treatments which patients
find unpleasant, such as intravenous adenosine, and may
reduce the time patients spend in the ED. We have also
built-in processes to empower patients to try these techni-
ques out of hospital. A better VM for use by patients them-
selves would give them more control and may reduce the
need for hospital attendance. If the trial shows that the
modified VM is more effective, the challenge will be the
dissemination of the technique to patients as well as staff.
Collaboration with patient support groups in the delivery
of this trial is an important part of its design, and lays the
foundations to meet this challenge.
Conclusions
The REVERT trial will seek to determine whether a simple
postural modification to the VM improves cardioversion
rates in adult patients presenting to the ED with SVT. It is
an important trial for people with SVT and the healthcare
staff who are involved in their care. The results of the study
could lead to a significantly improved VM and reduce the
need for patients to be treated with more invasive treat-
ments during attacks, saving time in the ED and poten-
tially avoiding the need to attend hospital altogether, if
successfully employed by patients themselves.
Author affiliations
1Department of Emergency Medicine, Royal Devon and Exeter Hospital NHS
Foundation Trust, Exeter, Devon, UK
2Department of Emergency Medicine, Musgrove Park Hospital NHS
Foundation Trust, Taunton, UK
Appelboam A, Reuben A, Mann C, et al. BMJ Open 2014;4:e004525. doi:10.1136/bmjopen-2013-004525 7
Open Access
group.bmj.com on January 9, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
3Arrhythmia Alliance, Stratford-upon-Avon, UK
4Research Design Service South West, University of Exeter Medical School,
Taunton, UK
5Faculty of Health and Life Sciences, University of the West of England,
Bristol, UK
6Peninsula Clinical Trials Unit, Plymouth University, Plymouth, UK
Acknowledgements The authors would like to acknowledge and thank
Corinna Phillips, Peninsula Clinical Trials Unit, for all her hard work and
administrative skills in support of this project and Paula Garrett, our patient
representative, for her help and advice in the ethics application and her views
on the protocol and research plans. They would also like to thank Mark Dayer
and Andrew Sharp for their expert and independent ECG review for the study.
Contributors AA conceived the idea for the study. AA, AR, CM were
responsible for the initial study design, which was refined with the help of PE,
AB, JB and JG and support of our regional National Institute for Health
Research (NIHR) Research Design Service. PE provided the statistical plan
and JG the background information and audit data for the trial. TL
represented the public and patient views in the study development. The Heart
Charity, which TL leads, provided patient testimonies that helped inspire the
trial design. All authors contributed to the final study design and protocol
development, critically revised successive drafts of the manuscript and
approved the final version. The trial management group is responsible for the
conduct of the study, overseen by a Trial Steering Committee.
Funding This research project is funded by the National Institute for Health
Research (NIHR) through its Research for Patient Benefit (RfPB) Programme
(Grant Reference Number PB-PG-0211-24145).
Competing interests None.
Ethics approval The study has been approved by the South West—Exeter
Research Ethics Committee (REC reference 12/SW/0281) and each of the
participating NHS Trust’s Research and Development departments.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement This is an Open Access article distributed in
accordance with the Creative Commons Attribution Non Commercial (CC
BY-NC 3.0) licence, which permits others to distribute, remix, adapt, build on
this work non-commercially, and licence their derivative works on different
terms, provided the original work is properly cited and the use is
non-commercial. http://creativecommons.org/licenses/by-nc/3.0/.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Orejarena LA, Vidaillet H, DeStefano F, et al. Paroxysmal
supraventricular tachycardia in the general population. J Am Coll
Cardiol 1998;31:150–7.
2. http://www.heartrhythmcharity.org.uk/www/218/0/Patient_stories/
(accessed Jun 2013).
3. Wood KA, Drew BJ, Scheinman MM. Frequency of disabling
symptoms in supraventricular tachycardia. Am J Cardiol
1997;79:145–9.
4. Murman DH, McDonald AJ, Pelletier AJ, et al. US emergency
department visits for supraventricular tachycardia, 1993-2003.
Acad Emerg Med 2007;14:578–81.
5. Cohn AE, Fraser FR. Paroxysmal tachycardia and the effect of
stimulation of the vagus nerves by pressure. Heart 1914;5:93–108.
6. Resuscitation Council (UK) Resuscitation Guidelines 2005. http://
www.resus.org.uk/pages/guide.htm
7. Gaspar JL. Comparing valsalva manoeuvre with carotid sinus
massage in adults with supraventricular tachycardia. BestBets, 2005.
http://www.bestbets.org
8. Taylor DM, Wong LF. Incorrect instruction in the use of the Valsalva
manoeuvre for paroxysmal supraventricular tachycardia is common.
Emerg Med Aust 2004;16:284–7.
9. Smith G, Morgans A, Boyle M. Use of the Valsalva manoeuvre in
the prehospital setting: a review of the literature. Emerg Med J 2009;
26:8–10.
10. Lim SH, Anantharaman V, Teo WS, et al. Comparison of treatment
of supraventricular tachycardia by Valsalva manoeuvre and carotid
sinus massage. Ann Emerg Med 1998;31:30–5.
11. Innes JA. Review article: adenosine use in the emergency
department. Emerg Med Aust 2008;20:209–15(7).
12. Smith GD, Dyson K, Taylor D, et al. Effectiveness of the Valsalva
manoeuvre for reversion of supraventricular tachycardia. Cochrane
Database Syst Rev 2013:3:CD009502.
13. Wong LF, Taylor DM, Bailey M. Vagal response varies with Valsalva
manoeuvre technique: a repeated measures clinical trial in healthy
subjects. Ann Emerg Med 2004;43:477–82.
14. Walker S, Cutting P. Impact of modified Valsalva manoeuvre in the
termination of paroxysmal SVT. Emerg Med J 2010;27:287–91.
15. Chance JF, Warner JG, Elsawy T. Augmented Valsalva manoeuvre
for supraventricular tachycardia in the young. J Clin Neurophysiol
1998;15:535–40.
16. Modified Valsalva Manoeuvre to treat recurrent supraventricular
tachycardia: description of the technique and its successful use in a
patient with a previous near fatal complication of DC cardioversion.
In submission to BMJ Case Reports. Maunscript No: bcr-2013-
202699.
17. Looga R. The Valsalva manoeuvre—cardiovascular effects and
performance technique: a critical review. Respir Physiol Neurobiol
2005;147:39–49.
18. Gagg J. Southwest SVT survey: current Valsalva manoeuvre
techniques in adults with supraventricular tachycardia. EMTA
Conference; Bristol (Poster, April 2011).
19. Smith G, Boyle M. The 10 mL syringe is useful in generating the
recommended standard of 40mmHg intrathoracic pressure for the
Valsalva manoeuvre. Emerg Med Aust 2009;21:449–54.
20. http://www.consort-statement.org/
8 Appelboam A, Reuben A, Mann C, et al. BMJ Open 2014;4:e004525. doi:10.1136/bmjopen-2013-004525
Open Access
group.bmj.com on January 9, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
(REVERT) study
Effectiveness in Re-entrant Tachycardias 
Randomised Evaluation of modified Valsalva
Gagg
Ewings, Jonathan Benger, Jane Vickery, Andrew Barton and James 
Andrew Appelboam, Adam Reuben, Clifford Mann, Trudie Lobban, Paul
doi: 10.1136/bmjopen-2013-004525
2014 4: BMJ Open 
 http://bmjopen.bmj.com/content/4/3/e004525
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/4/3/e004525
This article cites 14 articles, 2 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/3.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 3.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (160)Patient-centred medicine
 (260)Evidence based practice
 (97)Emergency medicine
 (354)Cardiovascular medicine
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 9, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
